Biogen’s ambitions in gene therapy hit by another failed pivotal trialWhen Biogen acquired Nightstar Therapeutics in 2019, it added a pair inherited retinal disorder (IRD) gene therapies that Share XBiogen’s ambitions in gene therapy hit by another failed pivotal trialhttps://pharmaphorum.com/news/biogens-ambitions-in-gene-therapy-are-hit-by-a-second-failed-phase-3-trial/
Biogen buys UK gene therapy firm Nightstar for $800mBiogen has agreed to buy UK-based gene therapy biotech Nightstar, which focuses on using modified viruses as therapies Share XBiogen buys UK gene therapy firm Nightstar for $800mhttps://pharmaphorum.com/news/biogen-buys-uk-gene-therapy-firm-nightstar-for-800m/
